PDCD1 and non-small cell lung carcinoma: An increase in PD-1+Ki67+CD8+ T cells in peripheral blood after PD-1 inhibitor treatment is associated with better outcomes in patients with NSCLC (Kamphorst et al., 2017; Kim et al., 2019).